Navigation Links
Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz
Date:8/23/2014

Albany, NewYork (PRWEB) August 23, 2014

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

Full Report With TOC @ http://www.researchmoz.us/critical-care-therapeutics-in-major-developed-markets-to-2020-new-and-late-stage-four-factor-pccs-and-recombinant-products-to-drive-market-report.html

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
  • Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
  • Key drivers and restraints that have had and are expected to have a significant impact on the market
  • An overview of major licensing and co-development agreements that could affect growth trends

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

Reasons to Buy

  • The report will enhance your decision-making capability by allowing you to:
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

For More Information Kindly Contact:
Email: sales(at)researchmoz(dot)us   
Blog: http://industryresearchnews.blogspot.com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12114682.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Primary care physicians can be critical resource for abused women in rural areas
2. CHEST releases new expert guidance in care of the critically ill and injured
3. Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting
4. Proteins critical to wound healing identified
5. United Nations Foundation Mobilizes Critical Support for the Millennium Development Goals
6. Central Ohio Trauma System (COTS) Relies on Onset Technology's OnPage® Critical Messaging Alerts System When Disaster Strikes
7. European Super Critical Fluid Chromatography Reagents Market is Expected to Reach $75.5 million in 2018 - New Report by MicroMarket Monitor
8. North America Super Critical Fluid Chromatography (Reagents) Market is Expected to Reach $107.8 Million in 2018 - New Report by MicroMarket Monitor
9. How critically ill infants can benefit most from human milk
10. Pyruvate oxidation is critical determinant of pancreatic islet number and β-cell mass
11. The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products ... newest mobility device, the StandUp Walker. Made entirely in the USA, the StandUp ... 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of ...
(Date:2/9/2016)... ... 2016 , ... Establishment Labs, a global breast implant and medical technology company, ... of Directors. , “We are honored to welcome David to our Board ... Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... grout cleaning and sealing company , is proud to announce that many of ... superior levels of customer service. The hard surface restoration franchises received customer recognition ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016 The new report "Global Blood Monitoring & Cardiac Monitoring Devices ... Consulting group reveals that global market for blood monitoring & cardiac ... expected to grow to US$ 24,830.1 million by 2019 at a ... America , Europe , Asia-Pacific ... and Africa . The three major ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson ... Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, ... Dominic Caruso , Vice President, Finance & Chief ... Consumer will represent the Company in a session scheduled ... . --> www.investor.jnj.com . --> ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will ... product line for long-term implant applications and announce ... Design & Manufacturing (MD&M) West Conference (Booth #1759), ... --> --> Available ... Biomedical LSRs offer outstanding physical properties enabling our ...
Breaking Medicine Technology: